Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYAD-101 in metastatic colorectal cancer
NCT03692429Phase 1Recruiting
- Sponsor
- Celyad Oncology
- Start
- Nov 2018
- Primary completion
- Nov 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label trial of CYAD-101 in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Celyad Oncology. Primary endpoint: Occurrence of Dose Limiting Toxicities. Started Nov 2018; status: recruiting.
02
Drugs
CYAD-101
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03692429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03692429.